The following article is sourced from Biotech Investment Notes, authored by Andy. As the technology of ADCs (Antibody-Drug Conjugates) evolves from the “first generation” to the “new generation”, bispecific ADCs and dual payload ADCs have emerged as two major research directions in the industry, breaking through the traditional single-target, single-payload ADCs. Although both are designed … Read more
“Structure similar to a bottlebrush” In recent years, antibody-drug conjugates (ADCs) have emerged as a novel targeted therapy strategy, achieving precise targeting of cancer cells by covalently linking monoclonal antibodies with small molecule drugs. They have demonstrated good efficacy and safety in the treatment of various cancers. However, traditional ADCs still face many limitations in … Read more
This is a short paper. It is not recommended to do this in practice, but it is theoretically acceptable. The reason is that the dynamic range is not 1+1=2, but rather <2. Moreover, in 2025, the performance of devices has improved significantly; the simpler, the better. Complex signal chains do not provide much performance improvement … Read more
Name Farnesane Farnesane Chemical Name 2,6,10-trimethyldodecane Molecular Formula C15H32 Molecular Weight 212.42 Catalog Number 1800215 Batch Number F251Q0 CAS 3891-98-3 Specification 25 mg Structural Formula _ Previous Issues Selected Text Editor: XC • Click the top left of this article “USP“ | Click the top right “… symbol | Select “Set as Favorite”
*For reference by medical professionals only Compiled by | Da Gao Ge According to global cancer statistics, the incidence of female cancers is on a continuous rise, particularly with breast cancer and ovarian cancer showing significant rates and disease burden. In the clinical diagnosis and treatment of these diseases, how to break through the efficacy … Read more
Click to follow Xiaobai Learning MedicineIntroduction: Since the approval of the first ADC drug Mylotarg® (Gemtuzumab Ozogamicin) in 2000, the number of ADC drugs has exploded, with 14 types of ADCs approved for market, and hundreds of ADC drugs undergoing clinical trials for various tumor indications. While ADCs are effective, their clinical development and application … Read more
Several high-value BD cases in 2025 have sparked strong interest in the Chinese biopharmaceutical sector from the capital market. China has become a major force in global BD output, thus examining the licensing pipelines of domestic biopharmaceutical companies can roughly analyze the direction of global pharmaceutical innovation. In the first half of this year, ADC … Read more
Click the arrow to follow us with the “blue text”! 1. 20ins Mutation: The ‘Hard-to-Treat Code’ of the EGFR Family The EGFR exon 20 insertion (20ins) mutation accounts for 4%-12% of NSCLC. Due to the unique mutation site, traditional EGFR-TKIs (such as gefitinib and osimertinib) struggle to bind effectively, leading to its classification as a … Read more
![RISC-V New Benchmark! In-Depth Testing of the Qinheng CH32V307 Development Board [Domestic MCU Column Issue 122]](https://boardor.com/wp-content/uploads/2025/11/c568101e-9dcc-410b-9d69-5667a4367408.jpg)
Qinheng USB Bluetooth MCU Forum https://bbs.21ic.com/iclist-900-1.html *Reading Instructions: The following is a brief summary display, with no specific order of ranking. For detailed evaluation processes, source code, and materials, please click the original link to view. Evaluation One 1. Unboxing: Industrial Grade New Benchmark https://bbs.21ic.com/icview-3457910-1-1.html The original factory packaging box is labeled with Qinheng, and … Read more
*For reference by medical professionals only ADC drugs reshape the stratified treatment strategy for HR+ advanced breast cancer In recent years, the rapid development of antibody-drug conjugates (ADC) has brought groundbreaking progress to the treatment of advanced breast cancer.Trastuzumab deruxtecan (T-DXd) and datopotamab deruxtecan (Dato-DXd) are representative drugs that are profoundly changing the treatment landscape … Read more